Journal article

Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study

Ursula Schmidt-Erfurth, Bora Eldem, Robyn Guymer, Jean-Francois Korobelnik, Reinier O Schlingemann, Ruth Axer-Siegel, Peter Wiedemann, Christian Simader, Margarita Gekkieva, Andreas Weichselberger

Ophthalmology | ELSEVIER SCIENCE INC | Published : 2011

DOI: 10.1016/j.ophtha.2010.09.004

Grants

Funding Acknowledgements

Peter Wiedemann - Lecture Fee - Novartis Pharmaceutical CorporationSupported by Novartis Pharma, AG, Switzerland.

Citation metrics

246Web of Science
284Scopus

Keywords

Fluorescein Angiography
Male
Life Sciences & Biomedicine
Antigen
Tomography, Optical Coherence
Antibodies, Monoclonal
Aged, 80 and Over
Drug Administration Schedule
Ranibizumab
Humans
Vascular Endothelial Growth Factor a
Excite Study Group
Retina
Ophthalmology
Macular Degeneration
Science & Technology
Therapy
Verteporfin
Double-Blind Method
Antibodies, Monoclonal, Humanized
Visual Acuity
Angiogenesis Inhibitors
Treatment Outcome
Aged
Intravitreal Injections
Middle Aged
Endothelial Growth-Factor
Female
Choroidal Neovascularization